Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pelareorep + atezolizumab + gemcitabine + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Oncolytics Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
pelareorep + atezolizumab + gemcitabine + nab-paclitaxel is an investigational combination regimen being evaluated for the first-line treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The regimen combines pelareorep (an intravenously administered, non-genetically modified oncolytic reovirus that selectively replicates in RAS-upregulated tumor cells) with atezolizumab (an anti-PD-L1 immune checkpoint inhibitor) and the standard-of-care chemotherapy doublet gemcitabine and nab-paclitaxel (GnP). Pelareorep acts by directly lysing cancer cells and promoting an inflamed tumor microenvironment, which synergizes with atezolizumab to overcome the highly immunosuppressive nature of pancreatic tumors. This combination has demonstrated promising efficacy and immune conversion activity in Cohort 1 of the Phase 1/2 GOBLET trial, receiving Fast Track Designation from the FDA.
- Other names
- pelareorep + atezolizumab + gemcitabine/nab-paclitaxelpelareorep + atezolizumab + GnP
02
Targets
CD80 (T-lymphocyte activation antigen CD80)DNAJAM-A (Junctional adhesion molecule A)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)EIF2AK2 (Interferon-induced protein kinase R)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))EIF2S1 (Eukaryotic translation initiation factor 2 alpha subunit)
Beyond the preview
Go deeper on pelareorep + atezolizumab + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pelareorep + atezolizumab + gemcitabine + nab-paclitaxel.